Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 196 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovarian Cysts Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women

NCT00413179
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Anovulation, Oligoovulation, Infertility, Hyperandrogenism
Interventions
Metformin, Clomiphene citrate, Placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

NCT03951077
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Elagolix, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • San Diego, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Early Phase 1 Interventional

Why do Oral Contraceptives Prevent Ovarian Cancer?

NCT02155777
View directory record Official record
Conditions
Ovarian Cancer Risk, Risk-reducing Surgery, Fallopian Tube Fimbriae, Ovarian Cortical Inclusion Cysts
Interventions
OrthoNovum 1/35
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 45 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

NCT01889199
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn Early Phase 1 Interventional

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422707
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 20, 2026, 5:31 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Elix Cycle Balance and Daily Harmony on Polycystic Ovary Syndrome

NCT05875233
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Elix Daily Harmony, Elix Cycle Balance
Other
Lead sponsor
Zenchi, Inc.
Industry
Eligibility
18 Years to 36 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PCOS and Brain Health

NCT07727512
View directory record Official record
Conditions
PCOS
Interventions
MRI Visit, Laboratory Visit
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT

NCT01672801
View directory record Official record
Conditions
Unexplained Infertility, Polycystic Ovarian Syndrome, Anovulatory
Interventions
Placebo, Nimodipine
Drug
Lead sponsor
Boston IVF
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 20, 2026, 5:31 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

NCT03905603
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
ACTH, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn Early Phase 1 Interventional

Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422096
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Leuprolide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

NCT00704912
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Heat Therapy and Cardiometabolic Health in Obese Women

NCT03644524
View directory record Official record
Conditions
Obesity, Polycystic Ovary Syndrome, Prehypertension, PreDiabetes, Cardiovascular Risk Factor, Metabolic Syndrome
Interventions
Heat therapy
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 20, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Lifestyle Markers Between Women With and Without Polycystic Ovary Syndrome

NCT01859663
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Dietary Habits, Physical Activity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
3
States / cities
Ithaca, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Metabolic Syndrome in PCOS: Precursors and Interventions

NCT00442689
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Metabolic Syndrome
Interventions
flutamide, ethinyl estradiol 35 mcg and drospirenone 3 mg, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Phase 1 Interventional

E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study

NCT07706374
View directory record Official record
Conditions
Poly Cystic Ovary Syndrome
Interventions
Exemestane 25 MG, Placebo, Exemestane 50 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Not applicable Interventional

This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.

NCT07764328
View directory record Official record
Conditions
Polycystic Ovarian Syndrome (PCOS)
Interventions
A dietary supplement powder for women, Placebo
Dietary Supplement
Lead sponsor
Mila Mend Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)

NCT00907153
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Vitamin D, Placebo
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 20, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point of Care 3D Ultrasound for Various Applications: A Pilot Study

NCT02831556
View directory record Official record
Conditions
Appendicitis, Evidence of Cholecystectomy, Gallstones, Pregnancy, Ectopic, Aortic Aneurysm, Kidney Stones, Intrauterine Pregnancy, Diverticulitis, Abdominal Injuries, Tumors, Pancreatitis, Digestive System Diseases, Gastrointestinal Diseases, Intraabdominal Infections, Intestinal Diseases, Pregnancy, Vascular Disease, Uterine Fibroids, Ovarian Cysts, Uterine Abnominalies, Bladder Abnominalies, Testicular Abnominalies, Polyps
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Completed No phase listed Observational

Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)

NCT01070160
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Endometrin (progesterone 100mg vaginal inserts), Metformin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 20, 2026, 5:31 PM EDT
Suspended Phase 3 Interventional

Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery

NCT00865488
View directory record Official record
Conditions
Ovarian Cysts, Endometriosis, Adhesions
Interventions
ADHEXIL
Biological
Lead sponsor
OMRIX Biopharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2009 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Liver and Fat Regulation in Overweight Adolescent Girls

NCT02157974
View directory record Official record
Conditions
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions
Byetta 5Mcg Pen Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Not applicable Interventional

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

NCT06049420
View directory record Official record
Conditions
Obesity, Hyperlipidemias, Polycystic Ovary Syndrome, Hypertension, Coronary Heart Disease, Heart Failure, Depression, Anxiety, Type II Diabetes, Metabolic Syndrome
Interventions
Lifestyle counseling and coaching
Behavioral
Lead sponsor
West Virginia School of Osteopathic Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lewisburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 20, 2026, 5:31 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ovarian Contribution to Androgen Production in Adolescent Girls

NCT01421810
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obesity, Hyperandrogenism
Interventions
Dexamethasone, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of Estrogen in Luteinizing Hormone Surge and Ovulation

NCT01999569
View directory record Official record
Conditions
Ovulation Disorder, Ovarian Cysts
Interventions
Letrozole
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 20, 2026, 5:31 PM EDT